N/A
N=14
Muscle Capillarization and Sarcopenia
Sarcopenia
Bottom Line
View on ClinicalTrials.gov: NCT03984994 ↗Enrolled (actual)
14
Serious AEs
0.0%
Results posted
Oct 2025
Primary outcome: Primary: Skeletal Muscle Capillarization — 0.4; 0.2 capillaries per muscle fiber — p=0.27
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Aerobic exercise training (Other); Strength training (Other)
- Age
- Older Adult · 65+ yrs
- Sex
- All
- Sponsor
- Baltimore VA Medical Center
- Primary completion
- Apr 2024
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Skeletal Muscle Capillarization |
0.4; 0.2 | 0.27 |
| PRIMARY Quadriceps Muscle Cross-sectional Area |
2.5; 0.7 | 0.22 |
| SECONDARY Skeletal Muscle Fiber Size |
607; 356 | 0.21 |
| SECONDARY Muscle Strength |
12.7; 2.0 | 0.28 |
Summary
Aging is associated with a loss of muscle mass, termed sarcopenia, that reduces mobility, decreases physical function and accelerates progression of other age-related disorders. This study is designed to determine whether increasing skeletal muscle capillarization through aerobic exercise will enhance muscular adaptations to strength training in older adults with sarcopenia.
Eligibility Criteria
Inclusion Criteria
- Body Mass Index = 18-32.5 kg/m2
- Non-smoker
- Presence of at least moderate sarcopenia (low muscle mass per unit body height)
Exclusion Criteria
- Diagnosis of diabetes, cancer, pulmonary or renal disease
- Physical impairment preventing exercise
- Recent history of exercise training
Data sourced from ClinicalTrials.gov (NCT03984994). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.